Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
1(6%)
Results Posted
30%(3 trials)
Terminated
1(6%)

Phase Distribution

Ph early_phase_1
1
6%
Ph not_applicable
4
24%
Ph phase_3
3
18%
Ph phase_2
4
24%
Ph phase_4
2
12%
Ph phase_1
3
18%

Phase Distribution

4

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution17 total trials
Early Phase 1First-in-human
1(5.9%)
Phase 1Safety & dosage
3(17.6%)
Phase 2Efficacy & side effects
4(23.5%)
Phase 3Large-scale testing
3(17.6%)
Phase 4Post-market surveillance
2(11.8%)
N/ANon-phased studies
4(23.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

10 of 14 finished

Non-Completion Rate

28.6%

4 ended early

Currently Active

1

trials recruiting

Total Trials

17

all time

Status Distribution
Active(1)
Completed(10)
Terminated(4)
Other(2)

Detailed Status

Completed10
Withdrawn3
unknown2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
1
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (5.9%)
Phase 13 (17.6%)
Phase 24 (23.5%)
Phase 33 (17.6%)
Phase 42 (11.8%)
N/A4 (23.5%)

Trials by Status

recruiting16%
terminated16%
withdrawn318%
unknown212%
completed1059%

Recent Activity

1 active trials
Showing 5 of 17
recruitingphase_4

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

NCT06218199
completedphase_2

Blood Pressure Management in Stroke Following Endovascular Treatment

NCT04484350
completedphase_2

Blood Pressure After Endovascular Stroke Therapy-II

NCT04116112
completednot_applicable

Efficacy of Nifedipine Versus Hydralazine in Management of Severe Hypertension in Pregnancy

NCT04435210
completedearly_phase_1

Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients

NCT03423810
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT06218199Phase 4

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

Recruiting
NCT04484350Phase 2

Blood Pressure Management in Stroke Following Endovascular Treatment

Completed
NCT04116112Phase 2

Blood Pressure After Endovascular Stroke Therapy-II

Completed
NCT04435210Not Applicable

Efficacy of Nifedipine Versus Hydralazine in Management of Severe Hypertension in Pregnancy

Completed
NCT03423810Early Phase 1

Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients

Completed
NCT02050529Phase 2

Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.

Completed
NCT02933593Not Applicable

Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols

Withdrawn
NCT00223717Phase 1

Treatment of Supine Hypertension in Autonomic Failure

Completed
NCT01822808Phase 3

Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure

Unknown
NCT00575978Phase 1

Hydralazine as Demethylating Agent in Breast Cancer

Withdrawn
NCT00575640Phase 1

Hydralazine as a Demethylating Agent in Rectal Cancer

Withdrawn
NCT02343393Phase 3

Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study

Unknown
NCT00607477Not Applicable

Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension

Terminated
NCT00000499Phase 2

Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)

Completed
NCT01538875Phase 3

Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy

Completed
NCT00661895Phase 4

Black Education and Treatment of Hypertension (BEAT HTN)

Completed
NCT00599235Not Applicable

Sildenafil and Exercise Capacity in Hypertension

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17